BiOptic has certificated by UL in conformance with FDA 21 CFR Part 11
2021-02-19
The software system of Qsep series bio-fragment analyzer, Q-Analyzer, which is developed by BiOptic, has certificated by UL in conformance with FDA 21 CFR Part 11 in Jan 2021. The FDA guidelines for Data Integrity include the requirement for compliance for the storage of electronic records. Nearly all the medical-related industries follow this standard, which gains on the safety of information security and data management of the product. The data retained in this standard can be used as an effective source for future tracking.
Compared to the past, high school students nowadays have more options for them to apply in the field they are interested in. However, not all of them are able to figure out what they would devoted to in the future at that age. Although there is a lot of course information on the website, what they cannot imagine is how to apply the knowledge they learned from university to their career. To fill up the gap between school and workplace, universities began to invite companies to participate summer/winter camps. Moreover, this could assist students in exploring their interests.
As the weather turned cooler in parts of the northern hemisphere, the COVID-19 pandemic is getting serious again in lots of countries. From the beginning of this pandemic, every health organization around the world has put a lot of efforts on finding the right strategy to stop it. Somehow, it seems that there is no effective way.
Rapid, Automated and High-Resolution Nucleic Acid Quality Control Solutions for NGS using CE
2021-01-14
Nucleic acid Quality Control (QC) is an essential component of next-generation sequencing (NGS) workflow. Verifying nucleic acid quality and concentration at checkpoints – from genomic DNA (gDNA) integrity check to final library fragment distribution check – helps to ensure successful sequencing outcomes.
Thanks for the efforts of our distributors all over the world. Although COVID-19 crushes the world economy, BiOptic is still growing while facing this pandemic. Due to the increasing number of orders, our production efficiency almost reaches its limit, so we decided to enlarge the space of our production line to fulfill the market demand. The headquarter of BiOptic Inc. will be relocated to the next building beside our existing ones from 12/19 to 12/20.
The consequences of the coronavirus disease (COVID-19) outbreak are unprecedented and felt around the world. Industries are being profoundly affected by the pandemic. Fortunately, BiOptic Inc. remains high productivity and keeps devoted to technological innovation. The outstanding R&D capabilities allow us to win several Technology Development Program (TDP) from the government and were favored by the committee of Taipei Biotech Awards – Innovation Award in July 2020.
